{
    "Trade/Device Name(s)": [
        "Access Toxo IgM II"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K242095",
    "Predicate Device Reference 510(k) Number(s)": [
        "K003259"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LGD"
    ],
    "Summary Letter Date": "July 17, 2024",
    "Summary Letter Received Date": "July 17, 2024",
    "Submission Date": "October 9, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.3780"
    ],
    "Regulation Name(s)": [
        "Toxoplasma gondii serological reagents"
    ],
    "Analyte Class(es)": [
        "serology",
        "immunology"
    ],
    "Analyte(s)": [
        "Toxoplasma gondii-specific IgM antibody"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Paramagnetic-particle immunoassay"
    ],
    "Methodologies": [
        "2-step (sandwich) chemiluminescence immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Quality control material",
        "Reagent",
        "Substrate",
        "Buffer"
    ],
    "Document Summary": "FDA 510(k) summary for Access Toxo IgM II assay for qualitative detection of Toxoplasma gondii-specific IgM antibody in adult human serum and plasma using chemiluminescent immunoassay technology.",
    "Indications for Use Summary": "Presumptive qualitative detection of Toxoplasma gondii-specific IgM antibody in adult human serum and plasma to aid diagnosis of acute, recent, or reactivated Toxoplasma gondii infection; recommended for use alongside a Toxoplasma gondii-specific IgG antibody assay.",
    "fda_folder": "Microbiology"
}